Replies to post #115384 on Biotech Values

[DewDiligence]

mcbio is the ARRY expert in these parts (#msg-59430105).

[mcbio]

Someone got a primer on ARRY. Looking to possibly add a position after dumping something today. What's coming up soon for the company that I should be aware of? Thank you

I'm certainly no expert but do keep dibs on ARRY since I'm long. As Dew pointed you to, see the ARRY RMF for somewhat organized info on ARRY, including notes on recent CCs. I think it's pretty clear that management is focused on the two MEK inhibitors as the key value drivers for the company. Both will report data later this year. The MEK partnered with AZN is apparently the furthest along MEK inhibitor in the clinic so this Phase 2 readout will give us an early indication on the utility of MEK inhibitors against cancer and this will be very key for ARRY. The other MEK with NVS will be reporting Phase 1b data so I'm not sure how meaningful that data will be to determine how useful this particular drug will be (it may still be too early stage to assess the utility of the drug and MEK inhibitors in general).

Either way, I am hoping to be out of my ARRY position entirely this year but not before the MEK data is reported. ARRY has a lot of debt due in 2014 and I'd prefer to be out of the stock this year because I believe that as we get closer and closer to 2014, the financial pressure will begin to mount on ARRY. I at least want to see what the MEK data does to the stock, though. Hopefully it will be positive but there's just no way of knowing of course.

[JJM760]

BTH

I'm doing some early spring cleaning and I'm thinking of getting out of CRIS. Can you convince it's a bad move?

Thanks, Joe